TEM
VENTE TOTALE: 139 887 titres (~7 023 296,81 $ US)
- Insiders
- Doudna Jennifer A, Epstein David R, West Nadja, LEFKOFSKY ERIC P
- Total bought
- —
- Total sold
- $7,023,297
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-03
TEM presents a mixed profile: moderate liquidity (65) and improving fundamentals are offset by persistent cash-flow negativity and high leverage (fundamentals score: 45), limiting conviction.
The first sentence of the analysis written for TEM on 2026-09-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 62.7% | 55.0% | 53.8% | 40.6% | 32.4% | |
| Ebit Margin | -17.4% | -93.4% | -31.3% | -83.3% | -94.4% | |
| Ebitda Margin | -9.3% | -88.0% | -25.1% | -73.9% | -85.1% | |
| Operating Profit Margin | -19.9% | -99.7% | -36.9% | -82.8% | -94.5% | |
| Pretax Profit Margin | -23.3% | -101.8% | -40.2% | -90.4% | -100.5% | |
| Continuous Operations Profit Margin | -19.3% | -101.8% | -40.3% | -90.4% | -100.5% | |
| Net Profit Margin | -19.3% | -101.8% | -40.3% | -90.4% | -100.5% | |
| Bottom Line Profit Margin | -19.3% | -107.6% | -50.0% | -104.1% | -115.5% | |
| Current Ratio | 3.134 | 2.294 | 1.506 | 2.517 | 3.519 | |
| Quick Ratio | 2.995 | 2.162 | 1.382 | 2.390 | 3.319 | |
| Solvency Ratio | -0.080 | -0.769 | -0.093 | -0.147 | -0.176 | |
| Cash Ratio | 1.624 | 1.171 | 0.713 | 1.739 | 2.419 | |
| Price To Earnings Ratio | -41.879 | -7.339 | -23.266 | -20.431 | -23.000 | |
| Price To Earnings Growth Ratio | 0.604 | -0.044 | 1.910 | -1.625 | -1.318 | |
| Forward Price To Earnings Growth Ratio | 0.604 | -0.044 | 1.910 | -1.625 | -1.318 | |
| Price To Earnings Diluted Ratio | -41.879 | -7.339 | -23.266 | -20.431 | -23.000 | |
| Price To Earnings Diluted Growth Ratio | 0.604 | -0.044 | 1.910 | -1.625 | -1.318 | |
| Price To Book Ratio | 20.944 | 97.148 | -4.490 | -6.056 | -8.468 | |
| Price To Sales Ratio | 8.091 | 7.893 | 11.668 | 21.323 | 26.517 | |
| Price To Free Cash Flow Ratio | -41.940 | -25.919 | -24.927 | -36.646 | -30.559 | |
| Price To Operating Cash Flow Ratio | -47.184 | -28.952 | -28.952 | -40.650 | -32.255 | |
| Debt To Assets Ratio | 0.583 | 0.505 | 0.865 | 0.686 | 0.450 | |
| Debt To Equity Ratio | 2.701 | 8.309 | -0.353 | -0.384 | -0.296 | |
| Debt To Capital Ratio | 0.730 | 0.893 | -0.546 | -0.622 | -0.420 | |
| Long Term Debt To Capital Ratio | 0.716 | 0.885 | -0.482 | -0.527 | -0.419 | |
| Financial Leverage Ratio | 4.630 | 16.438 | -0.408 | -0.559 | -0.658 | |
| Working Capital Turnover Ratio | 2.172 | 2.806 | 2.784 | 1.159 | 0.616 | |
| Operating Cash Flow Ratio | -0.586 | -0.649 | -0.921 | -0.965 | -1.846 | |
| Operating Cash Flow Sales Ratio | -0.171 | -0.273 | -0.403 | -0.525 | -0.822 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.125 | 1.117 | 1.161 | 1.109 | 1.056 | |
| Debt Service Coverage Ratio | -0.951 | -11.382 | -2.851 | -10.821 | -14.458 | |
| Interest Coverage Ratio | -3.599 | -12.881 | -4.184 | -12.124 | -16.051 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.164 | -0.404 | -0.439 | -0.388 | -0.887 | |
| Capital Expenditure Coverage Ratio | -7.999 | -8.546 | -6.193 | -9.153 | -18.015 | |
| Dividend Paid And Capex Coverage Ratio | -7.999 | -6.813 | -5.327 | -7.008 | -12.189 | |
| Dividend Payout Ratio | 0.000 | -0.008 | -0.026 | -0.019 | -0.022 | |
| Enterprise Value Multiple | -92.928 | -9.175 | -48.961 | -29.418 | -30.971 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 62.7% | ▲7.8% | ▲13.8% |
| Ebit Margin | -17.4% | ▲76.0% | ▲46.6% |
| Ebitda Margin | -9.3% | ▲78.7% | ▲47.0% |
| Operating Profit Margin | -19.9% | ▲79.8% | ▲46.9% |
| Pretax Profit Margin | -23.3% | ▲78.4% | ▲47.9% |
| Continuous Operations Profit Margin | -19.3% | ▲82.5% | ▲51.2% |
| Net Profit Margin | -19.3% | ▲82.5% | ▲51.2% |
| Bottom Line Profit Margin | -19.3% | ▲88.4% | ▲60.0% |
| Current Ratio | 3.134 | ▲0.841 | ▲0.540 |
| Quick Ratio | 2.995 | ▲0.834 | ▲0.546 |
| Solvency Ratio | -0.080 | ▲0.689 | ▲0.173 |
| Cash Ratio | 1.624 | ▲0.453 | ▲0.091 |
| Price To Earnings Ratio | -41.879 | ▼-34.540 | ▼-18.696 |
| Price To Earnings Growth Ratio | 0.604 | ▲0.648 | ▲0.699 |
| Forward Price To Earnings Growth Ratio | 0.604 | ▲0.648 | ▲0.699 |
| Price To Earnings Diluted Ratio | -41.879 | ▼-34.540 | ▼-18.696 |
| Price To Earnings Diluted Growth Ratio | 0.604 | ▲0.648 | ▲0.699 |
| Price To Book Ratio | 20.944 | ▼-76.204 | ▲1.128 |
| Price To Sales Ratio | 8.091 | ▲0.198 | ▼-7.007 |
| Price To Free Cash Flow Ratio | -41.940 | ▼-16.021 | ▼-9.942 |
| Price To Operating Cash Flow Ratio | -47.184 | ▼-18.232 | ▼-11.585 |
| Debt To Assets Ratio | 0.583 | ▲0.078 | ▼-0.035 |
| Debt To Equity Ratio | 2.701 | ▼-5.607 | ▲0.706 |
| Debt To Capital Ratio | 0.730 | ▼-0.163 | ▲0.723 |
| Long Term Debt To Capital Ratio | 0.716 | ▼-0.169 | ▲0.681 |
| Financial Leverage Ratio | 4.630 | ▼-11.808 | ▲0.741 |
| Working Capital Turnover Ratio | 2.171 | ▼-0.634 | ▲0.264 |
| Operating Cash Flow Ratio | -0.586 | ▲0.064 | ▲0.408 |
| Operating Cash Flow Sales Ratio | -0.172 | ▲0.101 | ▲0.267 |
| Free Cash Flow Operating Cash Flow Ratio | 1.125 | ▲0.008 | ▲0.011 |
| Debt Service Coverage Ratio | -0.951 | ▲10.431 | ▲7.141 |
| Interest Coverage Ratio | -3.599 | ▲9.282 | ▲6.169 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.164 | ▲0.239 | ▲0.292 |
| Capital Expenditure Coverage Ratio | -7.999 | ▲0.547 | ▲1.982 |
| Dividend Paid And Capex Coverage Ratio | -7.999 | ▼-1.185 | ▼-0.132 |
| Dividend Payout Ratio | 0.000 | ▲0.008 | ▲0.015 |
| Enterprise Value Multiple | -92.928 | ▼-83.754 | ▼-50.638 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.29B | $5.47B | $6.21B | $6.84B | $6.84B | |
| Enterprise value | $11.01B | $5.60B | $6.53B | $6.97B | $6.80B | |
| EV / Sales | 8.66x | 8.08x | 12.27x | 21.73x | 26.37x | |
| EV / Op. cash flow | -50.50x | -29.62x | -30.46x | -41.42x | -32.07x | |
| EV / Free cash flow | -44.88x | -26.52x | -26.22x | -37.34x | -30.39x | |
| EV / EBITDA | -92.93x | -9.18x | -48.96x | -29.42x | -30.97x | |
| Net debt / EBITDA | -6.09x | -0.21x | -2.42x | -0.55x | 0.18x | |
| Current ratio | 3.13x | 2.29x | 1.51x | 2.52x | 3.52x | |
| Income quality | 0.89x | 0.27x | 1.00x | 0.58x | 0.82x | |
| Graham net-net | -$4 | -$2 | -$11 | -$8 | -$6 | |
| Tax burden | 82.6% | 100.0% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 134.4% | 108.9% | 128.3% | 108.4% | 106.5% | |
| Working capital | $794.8M | $376.5M | $117.7M | $264.4M | $289.2M | |
| Invested capital | $1.77B | $534.4M | $295.2M | $422.6M | $377.8M | |
| Return on assets | -10.8% | -76.2% | -38.0% | -45.9% | -48.8% | |
| Operating ROA | -15.8% | -92.8% | -32.8% | -45.7% | -38.0% | |
| Return on tangible assets | -16.9% | -83.9% | -45.7% | -53.6% | -54.2% | |
| Return on equity | -49.9% | -1252.8% | 15.5% | 25.7% | 32.1% | |
| Return on invested capital | -10.9% | -107.7% | -58.0% | -57.3% | -58.4% | |
| Return on capital employed | -13.3% | -108.8% | -59.2% | -58.1% | -58.5% | |
| Earnings yield | -2.4% | -12.9% | -3.5% | -4.2% | -3.8% | |
| Free cash flow yield | -2.4% | -3.9% | -4.0% | -2.7% | -3.3% | |
| Capex / Op. cash flow | -12.5% | -11.7% | -16.1% | -10.9% | -5.6% | |
| Capex / Depreciation | 26.6% | 59.4% | 103.8% | 60.4% | 49.3% | |
| Capex / Sales | 2.1% | 3.2% | 6.5% | 5.7% | 4.6% | |
| SG&A / Sales | 56.3% | 108.9% | 55.8% | 72.8% | 77.2% | |
| R&D / Sales | 25.1% | 45.7% | 34.9% | 50.6% | 49.8% | |
| Stock comp / Sales | 9.8% | 77.0% | 0.0% | 0.0% | 0.2% | |
| Intangibles / Total assets | 36.3% | 9.2% | 16.9% | 14.3% | 10.0% | |
| Days sales outstanding | 92d | 81d | 65d | 101d | 116d | |
| Days payables outstanding | 63d | 63d | 81d | 88d | 71d | |
| Operating cycle | 132d | 126d | 108d | 144d | 164d | |
| Cash conversion cycle | 69d | 63d | 27d | 56d | 94d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+88.0%EV / Sales ▲+7.2%EV / EBITDA ▼-912.9%EV / Op. cash flow ▼-20.871Earnings yield ▲+0.105
Profitability
Return on equity ▲+12.029Return on assets ▲+0.654Return on invested capital ▲+0.968Return on capital employed ▲+0.955Operating ROA ▲+0.770Income quality ▲+0.622Tax burden ▼-0.175
Efficiency
Days sales outstanding ▲+10.331Days payables outstanding ▲+0.267Operating cycle ▲+5.304Cash conversion cycle ▲+5.037Capex / Sales ▼-0.010R&D / Sales ▼-0.206
Balance-sheet strength
Current ratio ▲+0.841Net debt / EBITDA ▼-5.887Working capital ▲+418254000.000Invested capital ▲+1239493000.000Intangibles / Total assets ▲+0.271
Change over 5 years
Valuation
Market cap ▲+50.5%EV / Sales ▼-67.2%EV / EBITDA ▼-200.1%EV / Op. cash flow ▼-18.424Earnings yield ▲+0.014
Profitability
Return on equity ▼-0.820Return on assets ▲+0.380Return on invested capital ▲+0.475Return on capital employed ▲+0.452Operating ROA ▲+0.222Income quality ▲+0.072Tax burden ▼-0.174
Efficiency
Days sales outstanding ▼-24.593Days payables outstanding ▼-7.566Operating cycle ▼-32.751Cash conversion cycle ▼-25.185Capex / Sales ▼-0.024R&D / Sales ▼-0.247
Balance-sheet strength
Current ratio ▼-0.385Net debt / EBITDA ▼-6.272Working capital ▲+505605000.000Invested capital ▲+1396055000.000Intangibles / Total assets ▲+0.263
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-16 | Nancy Pelosi | Purchase | $50,001 - $100,000 |
| 2025-05-09 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-01-14 | Nancy Pelosi | Purchase | $50,001 - $100,000 |
Recent news
- 2026-09-04 Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global H
- 2026-09-04 Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t.
- 2026-09-02 Why Moderna''s Cancer Vaccine Matters to Investors Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient''s unique biology.
- 2026-09-02 Tempus AI Director Nadja West Sells 3,000 Shares for $207,000 The disposition involved 3,000 shares executed at $69.00 per share, totaling $207,000 in transaction value on August 28, 2026. The shares traded were equal to 9.00% of the stake held before the filing, leaving the insider with a 0.0183% ownership interest.
- 2026-09-01 Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc''s (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
- 2026-09-01 Piper Sandler Lifts Tempus AI to Overweight at $76 Tempus AI (TEM) rose 2.46% premarket after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56. The firm had
- 2026-08-28 Cathie Wood Invested Roughly $1.4 Billion of Ark Invest''s Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks Wood is known for being a tech-first investor.
- 2026-08-26 Top Performing Leveraged/Inverse ETFs: 08/23/2026 Top Performing Leveraged/Inverse ETFs Last Week These were last week''s top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
- 2026-08-24 What''s Going On With Tempus AI Stock on Monday? Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.
- 2026-08-24 Best-Performing Leveraged ETF Areas of Last Week These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.